| Patent Number |
Title Of Patent |
Date Issued |
| RE38506 |
Potent inducers of terminal differentiation and methods of use thereof |
April 20, 2004 |
| The present invention provides the compound having the structure: ##STR1##wherein each of R.sub.1 and R.sub.2 are independently the same as or different from each other; when R.sub.1 and R.sub.2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamin |
| 7399461 |
Prostate-specific membrane antigen and uses thereof |
July 15, 2008 |
| This invention provides a method of administering methotrexate triglutamate (MTXglu3), an inhibitor of the neurocarboxypeptidase activity of prostate specific membrane antigen, to a subject so as to inhibit release of glutamate by N-acetylaspartylglutamic acid (NAAG) hydrolysis in th |
| 7384964 |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
June 10, 2008 |
| The present invention provides compounds of formula (I): ##STR00001## as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer comp |
| 7345174 |
Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
March 18, 2008 |
| The present invention provides the compound having the formula: ##STR00001## wherein each of R.sub.1 and R.sub.2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is a |
| 7271160 |
Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases |
September 18, 2007 |
| Bifunctional molecules comprising two hsp-binding moieties which bind to hsp90 in the pocket to which ansamycin antibiotics bind connected via a linker are effective for inducing the degradation and/or inhibition of HER-family tyrosine kinases. For example, a compound of two geldanamycin |
| 7267951 |
Method for evaluating a tissue or biopsy sample to determine if the sample is early-stage melano |
September 11, 2007 |
| A tissue or biopsy sample is evaluated to determine if the sample is early-stage melanoma by determining the level of inhibitor of DNA-binding protein 1 (Id1) expression in cells of the sample; and comparing the determined amount of Id1 to a reference level. The presence of levels of |
| 7247719 |
Primers and probes for amplification and detection of human inhibitor of DNA-binding |
July 24, 2007 |
| Oligonucleotide primers and polynucleotide probes provide selective amplification and detection of Id genetic sequences and are selected both (1) to provide the desired specificity so that they amplify only the specific Id type to which they are targeted; and (2) to introduce termina |
| 7244604 |
HDAC9 polypeptides and polynucleotides and uses thereof |
July 17, 2007 |
| The present invention features substantially pure HDAC9, HDAC9a, HDAC9(.DELTA.NLS), HDAC9a(.DELTA.NLS), an HDRP(.DELTA.NLS) polypeptides, and isolated nucleic acid molecules encoding those polypeptides. The present invention also features vectors containing HDAC9, HDAC9a, HDAC9(.DELT |
| 7238682 |
Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases |
July 3, 2007 |
| Bifunctional molecules comprising two hsp-binding moieties which bind to hsp90 in the pocket to which ansamycin antibiotics bind connected via a linker are effective for inducing the degradation and/or inhibition of HER-family tyrosine kinases. For example, a compound of two geldanamycin |
| 7211562 |
Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors |
May 1, 2007 |
| The administration of cytotoxic agents followed by the administration of heat shock protein 90 inhibitors, such as ansamycins, has a synergistic effect on the growth inhibition of cells. This synergy occurs at doses of each cytotoxic agent that normally only causes minimal growth inhibit |
| 7205142 |
Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof |
April 17, 2007 |
| The present invention provides an isolated nucleic acid molecule comprising sequences encoding the CA125 protein or a portion thereof. This invention also provides a method to detect ovarian cancer in a subject. Furthermore, this invention provides a method for the diagnosis of a can |
| 7199134 |
Hydroxamic acid compounds and methods of use thereof |
April 3, 2007 |
| The present invention relates to a novel class of hydroxamic acid derivatives having at least two aryl containing groups, at least one of which is a quinolinyl, isoquinolinyl or benzyl moiety, linked to the hydroxamic acid group through a methylene chain. The hydroxamic acid compound |
| 7160856 |
.alpha.-O-linked glycoconjugates, methods of preparation and uses thereof |
January 9, 2007 |
| The present invention provides novel .alpha.-O-linked glycoconjugates such as .alpha.-O-linked glycopeptides, as well convergent methods for synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell |
| 7148257 |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
December 12, 2006 |
| Methods for treating mesothelioma comprising administering the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) are disclosed. |
| 7144733 |
Bio-synthetic photostimulators and methods of use |
December 5, 2006 |
| Cells are rendered sensitive to stimulation by introducing into a non-photoreceptor cell nucleic acid sequences encoding at least an opsin gene product, an arrestin gene product, and the alpha subunit of the heterotrimeric G protein of the G.sub.q family. The introduced sequences are |
| 7126001 |
Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use there |
October 24, 2006 |
| The present invention provides the compound having the formula: ##STR00001## wherein each of R.sub.1 and R.sub.2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is a |
| 7124068 |
Crystal structure of a deacetylase and inhibitors thereof |
October 17, 2006 |
| The present invention provides three-dimensional structural information from the hyperthermophilic bacterium Aquifex aeolicus which is a histone deacetylase-like protein (HDLP). HDLP shares 35.2% amino acid sequence identity with human histone deacetylase (HDAC1). The present invention |
| 7122359 |
Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synth |
October 17, 2006 |
| The present invention provides mutant nucleotidylyl-transferases, such as E.sub.p, having altered substrate specificity; methods for their production; and methods of producing nucleotide sugars, which utilize these nucleotidylyl-transferases. The present invention also provides metho |
| 7115651 |
Macrocycles and uses thereof |
October 3, 2006 |
| The present invention relates to compounds having the structure (and pharmaceutically acceptable derivatives thereof) ##STR00001## wherein R.sub.0 R.sub.4, Z, X, A--B, D--E, G--J, and K--L are as defined herein, the synthesis thereof and the use of these compounds as therapeutic a |
| 7105159 |
Antibodies to prostate-specific membrane antigen |
September 12, 2006 |
| This invention provides purified antibodies to the outer membrane domain of prostate-specific membrane (PSM) antigen, compositions of matter comprising PSM antigen antibodies conjugated to a radioisotope or a toxin, and a method of imaging prostate cancer by using PSM antigen antibod |
| 7070782 |
Prostate-specific membrane antigen |
July 4, 2006 |
| The invention provides a purified prostate-specific membrane antigen. |
| 7063973 |
HDAC9 polypeptides and polynucleotides and uses thereof |
June 20, 2006 |
| The present invention features substantially pure HDAC9, HDAC9a, HDAC9(.DELTA.NLS), HDAC9a(.DELTA.NLS), an HDRP(.DELTA.NLS) polypeptides, and isolated nucleic acid molecules encoding those polypeptides. The present invention also features vectors containing HDAC9, HDAC9a, HDAC9(.DELT |
| 7045495 |
Combination of bryostatin and paclitaxel for treating cancer |
May 16, 2006 |
| This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase |
| 7041869 |
Transgenic luciferase mouse |
May 9, 2006 |
| The present invention provides a transgenic animal expressing the reporter gene, luciferase, driven by a promoter (e.g. the E2F1 promoter) that acts as a sensor of cell cycle. The luciferase substrate, luciferin, emits light when metabolized, and the light is transmitted through mammalia |
| 7038031 |
DNA encoding Fc.gamma.R receptor protein on NK cells |
May 2, 2006 |
| The present invention provides DNA encoding an Fc.gamma.RIII(CDl6) receptor protein expressed on NK cells. The invention also provides a stable cell line expressing the Fc.gamma.RIII(CDl6) from NK cells. Further provided is a method for determining the presence of HIV-enhancing antib |
| 7037647 |
Prostate-specific membrane antigen and uses thereof |
May 2, 2006 |
| This invention provides an isolated mammalian nucleic acid molecule encoding an alternatively spliced prostate-specific membrane (PSM') antigen. This invention provides an isolated nucleic acid molecule encoding a prostate-specific membrane antigen promoter. This invention provides a |
| 7026450 |
Ma family polypeptides and anti-Ma antibodies |
April 11, 2006 |
| Ma family polypeptides Ma1, Ma2, Ma3, Ma4 and Ma5 are disclosed, as are nucleic acids encoding the Ma family polypeptides, antibodies that bind to Ma family polypeptides, and methods of diagnosis of paraneoplastic syndromes, by assessing a test sample from an individual for the presence |
| 7026141 |
Topoisomerase-based reagents and methods for molecular cloning |
April 11, 2006 |
| This invention provides a modified vaccinia topoisomerase enzyme containing an affinity tag which is capable of facilitating purification of protein-DNA complexes away from unbound DNA. This invention further provides a modified sequence specific topoisomerase enzyme.This invention p |
| 7014856 |
Ganglioside-KLH conjugate vaccines plus OS-21 |
March 21, 2006 |
| This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effe |
| 7001601 |
Ganglioside-KLH conjugate vaccine plus QS-21 |
February 21, 2006 |
| This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effe |
| 6989383 |
Method of treating cancer |
January 24, 2006 |
| The present invention relates to methods of treating cancer using a combination of a compound which is an antineoplastic agent and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or s |
| 6972335 |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
December 6, 2005 |
| The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel |
| 6972170 |
Markers for prostate cancer |
December 6, 2005 |
| This invention provides a method for determining the aggressiveness of a prostate carcinoma comprising: (a) obtaining a sample of the prostate carcinoma; and (b) detecting the presence of p27 protein in the prostate carcinoma, the absence of p27 indicating that the prostate carcinoma is |
| 6967022 |
Ganglioside-KLH conjugate vaccines plus QS-21 |
November 22, 2005 |
| This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effe |
| 6965034 |
Synthesis of epothilones, intermediates thereto and analogues thereof |
November 15, 2005 |
| The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof, useful in the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. Also provided are intermediates useful for prepari |
| 6953668 |
Prostate-specific membrane antigen |
October 11, 2005 |
| This invention provides for an isolated mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane antigen. This invention provides for nucleic acid probes which specifically hybridize with the nucleic acid molecule encoding said antigen. This invention provides for |
| 6946456 |
Methods for treating cell proliferative disorders and viral infections |
September 20, 2005 |
| The present invention concerns methods for treating cell proliferative diseases, tumors associated with viral infections, and certain viral infections. The disclosed methods use compounds which inhibit heat shock protein 90 proteins. Such methods block Rb negative or deficient cells in |
| 6939948 |
GD2 peptide mimics |
September 6, 2005 |
| The present invention provides peptide mimics for GD2 ganglioside. The peptide mimics were identified by panning phage display peptide libraries with an anti-GD2 monoclonal antibody. The identified peptide mimics can be used as immunogens for cancer therapy such as for melanoma and n |
| 6936253 |
Ganglioside-KLH conjugate vaccines plus QS-21 |
August 30, 2005 |
| This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effe |
| 6921769 |
Synthesis of epothilones, intermediates thereto and analogues thereof |
July 26, 2005 |
| The present invention provides compounds of formula (I): ##STR1## as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer compri |
| 6916632 |
Methods and reagents for molecular cloning |
July 12, 2005 |
| The present invention provides compositions, methods, and kits for covalently linking nucleic acid molecules. The methods include a strand invasion step, and the compositions and kits are useful for performing such methods. For example, a method of covalently linking double stranded |
| 6897062 |
DNA encoding the prostate-specific membrane antigen-like gene and uses thereof |
May 24, 2005 |
| The present invention discloses a new gene, termed PSMA-like, that is very similar to the prostate-specific membrane antigen (PSMA) gene and cross-reacts with current detection methods for PSMA. The present invention also provides for a method of distinguishing the PSMA and PSMA-like |
| 6887887 |
Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor |
May 3, 2005 |
| The present invention provides methods for the asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and the compounds thereby synthesized having a structural formula: ##STR1##where R.sup.1 is an optionally substituted or halogenated alkyl, aryl, heteroalkyl or heteroaryl ami |
| 6887467 |
Double mutants of dihydrofolate reductase and methods of using same |
May 3, 2005 |
| New mutant forms of human dihydrofolate reductase (DHFR) which have properties superior to the previously disclosed mutants have mutations at both amino acid 22 and amino acid 31. Specific mutant forms are Ser31Tyr22, Ser31Phe22, Gly31Tyr22, Gly31Phe22, Ala31Tyr22 and Ala31Phe22. The |
| 6884604 |
Glycorandomization and the production of novel erythronolide and coumarin analogs |
April 26, 2005 |
| The present invention provides combinatorial methods for rapidly generating a diverse library of glycorandomized structures, comprising incubating one or more aglycons and a pool of NDP-sugars in the presence of a glycosyltransferase. The glycosyltransferase may be one that is associated |
| 6867305 |
Synthesis of epothilones, intermediates thereto and analogues thereof |
March 15, 2005 |
| The present invention provides convergent processes for preparing epothilones, desoxyepothilones, and analogues thereof. The present invention further provides novel compositions and methods for the treatment of cancer and additionally provides methods for the treatment of cancer whi |
| 6852533 |
Purified populations of stem cells |
February 8, 2005 |
| The invention is directed to a purified population of mammalian endothelial, muscle, or neural stem cells. The invention further provides methods for isolating such populations of cells; methods for using such populations of cells for treating mammals; methods for making vectors for |
| 6849651 |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
February 1, 2005 |
| The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel |
| 6838549 |
Human pluripotent hematopoietic colony stimulating factor, method of production and use |
January 4, 2005 |
| Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the g |
| 6828340 |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
December 7, 2004 |
| The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel |
